EV/EBITDA spoločnosti Cue Biopharma Inc
Aká je hodnota metriky EV/EBITDA spoločnosti Cue Biopharma Inc?
Hodnota metriky EV/EBITDA spoločnosti Cue Biopharma Inc je N/A
Aká je definícia metriky EV/EBITDA?
EV/EBITDA je podniková hodnota vydelená EBITDA (zisk pred odpočítaním úrokov, daní, odpisov, a amortizácie). Meria nákladnosť akcie a používa sa na porovnávanie spoločností medzi sebou častejšie ako P/E ratio. Meria cenu akú investor zaplatí za pohyb hotovosti v spoločnosti.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Cue Biopharma Inc
Čomu sa venuje spoločnosť Cue Biopharma Inc?
cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci
Firmy s metrikou ev/ebitda podobnou spoločnosti Cue Biopharma Inc
- Hodnota metriky EV/EBITDA spoločnosti Trilogy International Partners je N/A
- Hodnota metriky EV/EBITDA spoločnosti Worldwide je N/A
- Hodnota metriky EV/EBITDA spoločnosti Myanmar Investments International je N/A
- Hodnota metriky EV/EBITDA spoločnosti Oshidori International je N/A
- Hodnota metriky EV/EBITDA spoločnosti Target Capital je N/A
- Hodnota metriky EV/EBITDA spoločnosti Gold State Resources je N/A
- Hodnota metriky EV/EBITDA spoločnosti Cue Biopharma Inc je N/A
- Hodnota metriky EV/EBITDA spoločnosti Entheon Biomedical je N/A
- Hodnota metriky EV/EBITDA spoločnosti Vantex Resources Ltd je N/A
- Hodnota metriky EV/EBITDA spoločnosti Made.Com Plc Ord Gbp0.000 je N/A
- Hodnota metriky EV/EBITDA spoločnosti Skychain Technologies je N/A
- Hodnota metriky EV/EBITDA spoločnosti 5paisa Capital je N/A
- Hodnota metriky EV/EBITDA spoločnosti Catenae Innovation Plc je N/A